TSX Exchange Symbol: RVX
CALGARY, Jan. 2, 2014 /PRNewswire/ - Resverlogix Corp. (TSX: RVX) today announced that a publication titled "RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist" was published on December 31st 2013 in the international, peer-reviewed, open-access online publication PLOS ONE Journal. The publication was authored by Resverlogix staff in combination with collaborators from Xtal Biostructures Inc. in Maryland USA.
This publication is the third recent publication discussing the unique attributes of RVX-208. In October 2013 the Structural Genomics Consortium, in conjunction with a group of University of Oxford UK scientists, published a work titled "RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain". This paper was a peer reviewed publication in by the Proceedings of the National Academy of Sciences of the United States of America.
"The Structural Genome - Oxford paper was viewed by us as an extremely important publication as it confirmed by an external group for the first time that RVX-208 was the first known selective BET inhibitor thus highlighting Resverlogix' technological lead in the bromodomain space," said Donald J. McCaffrey, President & CEO of Resverlogix.
In August 2013 a third publication in the Cell Journal, titled "BET Bromodomains Mediate Transcriptional Pause Release in Heart Failure", used RVX-208 as one of the BET inhibitors that confirmed the potential for BET inhibitors as therapeutic targets in heart failure. The authors of this publication were primarily from various divisions of Harvard Medical School.
RVX-208 is a first-in-class small molecule that inhibits BET bromodomains. RVX-208 functions by removing atherosclerotic plaque via reverse cholesterol transport (RCT), the natural process through which atherosclerotic plaque is transported out of the arteries and removed from the body by the liver. RVX-208 increases production of Apolipoprotein A-I (ApoA-I), the key building block of functional high-density lipoprotein (HDL) particles and the type required for RCT. These newly produced, functional HDL particles are flat and empty and can efficiently remove plaque and stabilize or reverse atherosclerotic disease. Post-hoc analysis of recent clinical trials data showed that RVX-208 significantly reduces coronary atherosclerosis and major adverse cardiac events in patients with CVD who have a low level of HDL and elevated CRP, a population with unmet medical need. ApoA-I may also exert beneficial effects in Alzheimer's disease and Diabetes Mellitus.
Resverlogix Corp. (TSX:RVX) is a clinical stage biotechnology company developing compounds involving ApoA-I production. RVX-208 is a first-in-class small molecule in development for the treatment of diseases such as atherosclerosis, Diabetes Mellitus and Alzheimer's disease. RVX-208 is the first BET bromodomain inhibitor in clinical trials. Resverlogix's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com. We can be followed on our blog at http://www.resverlogix.com/blog.
Resverlogix IR App
This app gives Resverlogix investors mobile access to the latest stock data, news, and SEC Filings. It also provides proprietary company content including presentations, conference calls, videos, fact sheets, annual reports and other qualitative company information. Investors are able to receive 'push' notifications when new content is added to the IR App such as add events to calendars, share content and as well as download files for offline viewing.
To download the Resverlogix IR App, please visit your app store.
Apple Products (iPhone, iPad, and iPod's) - https://itunes.apple.com/WebObjects/MZStore.woa/wa/viewSoftware?id=730718904&mt=8
Android Products (Google Play, Tablets and Smartphones) - https://play.google.com/store/apps/details?id=com.theirapp.resverlogix
This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to research and development activities and the potential role of RVX-208 in the treatment of diseases such as atherosclerosis, Diabetes Mellitus and Alzheimer's disease. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Donald J. McCaffrey
President and CEO
SVP Business & Corporate Development
SOURCE Resverlogix Corp.